| advanced breast cancer (metastatic) | All results are NS for efficacy inferior to megestrol acetate in terms of nausea in Buzdar b, 1996 inferior to megestrol acetate in terms of vomiting in Buzdar c, 1996 inferior to megestrol acetate in terms of nausea in Buzdar c, 1996 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Bezwoda, 1998 | vs megestrol acetate | | | Clinical benefit (assessable) 0.74 [0.21; 2.57] Objective response (assessable) 0.92 [0.20; 4.33] overall survival (reported or calculated) 1.35 [0.49; 3.73] nausea 1.49 [0.66; 3.39] Objective response (randomised) 0.92 [0.20; 4.33] Clinical benefit (randomised) 0.74 [0.21; 2.57] hot flushes 2.90 [0.82; 10.27] | | Buzdar b, 1996 | vs megestrol acetate | | nausea 1.68 [1.06; 2.66] | Clinical benefit (assessable) 0.98 [0.75; 1.29] Objective response (assessable) 1.45 [0.87; 2.41] vomiting 1.88 [0.87; 4.07] diarrhoea 1.15 [0.64; 2.07] Objective response (randomised) 1.45 [0.87; 2.42] Clinical benefit (randomised) 0.99 [0.75; 1.30] arthralgia 0.55 [0.22; 1.36] rash 0.65 [0.31; 1.35] hot flushes 1.27 [0.70; 2.30] | | Buzdar c, 1996 | vs megestrol acetate | | vomiting 2.53 [1.31; 4.89] nausea 3.21 [1.96; 5.27] | Clinical benefit (assessable) 1.10 [0.83; 1.46] Objective response (assessable) 0.86 [0.47; 1.58] diarrhoea 0.88 [0.45; 1.69] Objective response (randomised) 0.86 [0.47; 1.57] Clinical benefit (randomised) 1.10 [0.83; 1.46] arthralgia 1.21 [0.62; 2.36] rash 1.38 [0.70; 2.71] hot flushes 1.29 [0.71; 2.32] | | Thuerlimann, 1996 | vs megestrol acetate | | | Clinical benefit (assessable) 1.02 [0.88; 1.19] Objective response (assessable) 1.34 [0.82; 2.19] overall survival (reported or calculated) 0.91 [0.39; 2.13] Objective response (randomised) 1.39 [0.85; 2.29] Clinical benefit (randomised) 1.06 [0.90; 1.25] thromboembolic 0.00 [0.00; NaN] rash ∞ [NaN; ∞] hot flushes 0.99 [0.61; 1.60] | | Falkson, 1996 | vs megestrol acetate | | | Objective response (assessable) 0.89 [0.55; 1.45] Objective response (randomised) 0.94 [0.57; 1.55] hot flushes 0.91 [0.51; 1.65] |
| Trial | Treatments | Patients | Method |
|---|
| Bezwoda, 1998 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Buzdar b, 1996 | (n=-9) vs. (n=-9) | postmenopausal patients with metastatic breast carcinoma: | Sample size: -9/-9 Primary endpoint: FU duration: | | Buzdar c, 1996 | (n=-9) vs. (n=-9) | postmenopausal patients with metastatic breast carcinoma | Sample size: -9/-9 Primary endpoint: FU duration: | | Thuerlimann, 1996 | (n=-9) vs. (n=-9) | postmenopausal women with advanced breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: | | Falkson, 1996 | (n=-9) vs. (n=-9) | previously untreated postmenopausal patients with metastatic breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
|
